Lglip 5 Tablet

Lglip 5 Tablet contains Linagliptin 5 mg. Prescription required.

Type 2 diabetes mellitus: used to improve glycaemic control in adults, as monotherapy or in combination with other antidiabetic medicines along with diet and exercise.

Linagliptin is a DPP-4 inhibitor. It increases levels of incretin hormones (GLP-1 and GIP), which enhance glucose-dependent insulin release and reduce glucagon secretion, lowering blood glucose with a low risk of hypoglycaemia when used alone.

Oral tablet. Usual adult dose: 5 mg once daily, with or without food, at the same time each day. Swallow whole with water. Dose adjustments and combination therapy should be as advised by a doctor.

Nasopharyngitis, cough, headache, diarrhoea, upper respiratory tract infection, hypersensitivity reactions (rash/urticaria), hypoglycaemia (more likely when used with sulfonylureas/insulin)

Not for type 1 diabetes or diabetic ketoacidosis. Stop and seek medical help if symptoms of pancreatitis occur (severe persistent abdominal pain). Rare severe joint pain and hypersensitivity/angioedema may occur. Monitor for hypoglycaemia when combined with insulin or sulfonylureas (dose reduction of those agents may be needed). Use with caution in severe hepatic impairment; generally no renal dose adjustment needed for linagliptin, but follow physician advice. Inform doctor about history of pancreatitis.

Insulin and sulfonylureas (increased hypoglycaemia risk), rifampicin and other strong P-gp/CYP3A4 inducers (may reduce linagliptin efficacy), carbamazepine/phenytoin/phenobarbital (may reduce effect), other antidiabetic drugs (additive glucose lowering)

Store below 25°C, in a dry place, protected from moisture and light. Keep in original blister pack and out of reach of children.

Trajenta 5 mg Tablet, Linagliptin 5 mg Tablet (generic), Lini 5 Tablet, Linaglip 5 Tablet, Linx 5 Tablet